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Diagnosis of Chlamydia trachomatis infections in a sexually transmitted
disease clinic: evaluation of a urine sample tested by enzyme
immunoassay and polymerase chain reaction in comparison
with a cervical and/or a urethral swab tested by culture and
polymerase chain reaction
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Objective To evaluate the value of a urine sample for diagnosing Chlamydia trachomatis
infection in an STD clinic in a prospective study of samples collected from 410 con-
secutive STD patients (167 female and 243 male).
Methods Urine samples were tested by enzyme immunoassay (EIA) and polymerase
chain reaction (PCR) in comparison with cervical and/or urethral swabs tested by PCR
and cell culture. A questionnaire was completed for a total of 320 patients concerning
symptoms, and determining whether they were controls, contacts or were being tested
subsequent to legal abortion.
Results The overall prevalence of C. trachomatis infection was 11.5%. At least 40% of
patients were asymptomatic. Of the C. trachomatis-positive patients, 85% were diagnosed
by testing urine, compared to 91% by testing swabs. For urine tests, the sensitivities of
PCR were 66.7% and 71.9% for female and male patients, respectively, and the sensitiv-
ities of EIA were 40.0% and 62.5%, or 46.7% and 71.9%, for female and male patients,
respectively, by including a 30% gray zone below the cut-off value. For swabs, the
sensitivities of PCRwere 93.3% and 87.5% for female andmale patients, respectively, and
equal to the sensitivities of culture. In total, 3.3% of controls and 35% of contacts were
found to be C. trachomatis positive.
Conclusion The use of urine samples for the diagnosis of C. trachomatis infections was
effective, but urine samples should be additional to conventional swab(s) instead of
replacing. Partner notiﬁcation and a conﬁrmation of cure is recommended.
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INTRODUCTION
Chlamydia trachomatis is today the most frequent
sexually transmitted microorganism in the Wes-
tern World, causing serious complications and
sequelae. In Denmark, almost 13 000 C. trachomatis
infections were diagnosed in 1998 (25% from male
patients and 75% from female patients), corre-
sponding to a prevalence of 4.7%, based on
approximately 270 000 analyses. A decrease in
the prevalence of at least 3.5% was observed from
1989 to 1998, but the number of analyses in the
same period of time was 2.7 times higher, which
could explain some of the observed decrease in
prevalence [1–3]. Because many infections are
asymptomatic [4–7], the only way to reduce the
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number of cases is by screening and treating selec-
tive groups [8–12]. A non-invasive method using a
urine sample seems suitable for this. Besides being
non-invasive, aurine sampleneedsnophysician for
sampling, and is suitable for ‘home collection’ [9].
In this prospective study of patients attending a
sexually transmitted disease (STD) clinic in
Copenhagen, Denmark, we compared a ﬁrst-catch
urine sample tested by two commercially available
tests—an enzyme immunoassay (EIA), Syva
Microtrak II EIA (Syva Company, San Jose, CA,
USA), and a polymerase chain reaction (PCR),
Amplicor (Roche Diagnostic Systems, F. Hoff-
man-La-Roche Ltd, Basel, Switzerland)—with a
cervical and/or urethral swab tested by culture
and PCR. The aim of the study was to clarify
whether a urine sample could replace the conven-
tional swabbing technique in this population.
MATERIALS AND METHODS
Study population
In total, 410 consecutive patients (243 males, med-
ian age 28 years (range 17–60 years) and 167
females, median age 25 years (range 16–69 years))
visiting a dermatovenerologic ‘walk-in’ clinic at
University Hospital, Rigshospitalet in Copenha-
gen from January 1995 to February 1996 were
enrolled in the study after written informed con-
sent according to the Helsinki Declaration II.
Approval of the study was obtained from the
regional scientiﬁc ethical committee.
Materials
From all patients, a 50-mL ﬁrst-void urine sample
was collected, at least 30min after last urination
from which two aliquots of 10mL were taken, one
for EIA and one for PCR. A urethral swab from
male patients, and a cervical swab together with a
urethral swab from female patients, were collected
for culture and PCR. Swabs (for PCR and culture)
were kept in culture transport media, and the same
swabs were used for PCR and culture. In order to
avoid bias for one specimen type, half of the
patients collected a urine sample before swabbing,
and the other half were swabbed before the urine
sample was collected.
In total, 320 questionnaires were completed,
concerning symptoms of urethritis (dysuria, ure-
thral discharge) and cervicitis (vaginal discharge,
bleeding), and determinedwhether a patient was a
control, was being tested 4 weeks after a legal
abortion, or had been in contact with a C. tracho-
matis-positive patient or had came for follow-up
examination 4 weeks after treatment for C. tracho-
matis infection with a single oral 1.0-g dose of
azithromycin.
METHODS
EIA and direct fluorescent assay on urine
samples
Urine samples were kept at 4 8C for a maximum of
3 days before reaching the laboratory. When the
urine samples had reached room temperature,
they were mixed and an aliquot of 4mL was taken
for Syva Microtrak II Chlamydia EIA (Syva Com-
pany). The rest of the urine sample (6mL)was kept
for direct ﬂuorescent assay (DFA) by the Syva
Microtrak Chlamydia trachomatis Direct Specimen
Test (Syva Company). The urine samples for EIA
as well as for DFA were centrifuged (3000 g for
30min), and for the EIA the pellet was processed
according to the manufacturer’s instructions.
For DFA, the pellet was washed by another
centrifugation with phosphate-buffered saline
(PBS) (pH7.4), and the pellet was then resus-
pended in 100 mL of PBS, from which 10–25 mL
was used for the slide preparation. Fixation and
staining of the slide was performed according to
the manufacturer’s instructions.
All positive EIA results (OD value cut-off) and
EIA gray-zone positive results (a gray zone was
deﬁned as a 30% zone below the cut-off value)
were tested byDFA on the EIA specimen remnants
or on the separate urine samples for DFA, as
described above.
Observation of one or more elementary bodies
(EBs) was considered as conﬁrmation of a positive
or a gray-zone-positive EIA result. All slides were
read by the same person throughout the whole
study.
PCR
The Amplicor Chlamydia trachomatis Test (Roche
Diagnostic Systems) was used for the PCR testing
of urine samples, urethral swabs and cervical
swabs. The urine samples for PCR were kept at
4 8C, and swabs for PCR were kept at 80 8C,
before further processing twice a week.
The PCR detects plasmid DNA. The automatic
COBAS Systemwas used for the samples collected
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from the last 61 patients. An internal control to
detect inhibitors in the sample causing a false-
negative result was incorporated in the COBAS
system, but not in the Amplicor Chlamydia tracho-
matis Test.
A gray-zone result, according to the manufac-
turer’s instructions, was an OD value between 0.2
and 0.5. All gray-zone-positive results were later
retested, and a PCR detecting major outer mem-
brane protein (MOMP PCR) was performed blind
by F. Hoffmann-La Roche, Ltd, Diagnostic Divi-
sion, Basel, Switzetland. The samples were stored
at 80 8C until testing.
Urine samples
Urine samples were tested according to the instruc-
tions of the manufacturer. Prior to PCR testing, the
urine sample was centrifuged at 1500 g for 10min,
and the pellet was used for further testing.
Swabs
Swabs were tested according to the instructions of
the manufacturer.
Culture
The swabs were cultured in cycloheximide-treated
McCoy cells [13] without blind passage, and inclu-
sion-forming units (IFUs) were detected by iodine
staining. The culture was read after 48 h and 72 h.
To achieve optimal culture result, the swabs
were transported on ice to the laboratory. Samples
were inoculated twice weekly. The samples were
kept at 80 8C prior to inoculation.
If one or more IFUs were observed, the sample
was considered positive.
Criteria for ‘true’ positive results
A culture-positive result was considered as ‘true’,
and needed no further conﬁrmation. A positive
EIA and PCR result or a gray-zone-positive EIA or
PCR result was considered a ‘true’ positive if it
could be conﬁrmed by a urine DFA or by aMOMP
PCR or if a parallel test result was a ‘true’positive.
Evaluation of a negative result
For every 15 sets of negative sample results (nega-
tive urine EIA result, negative urine PCR result,
negative swab PCR result, and negative swab
culture result), a separate urine sample was tested
by DFA. In total, 23 urine samples (representing 23
sets of negative samples) were tested by DFA. This
conﬁrmation was not performed blind.
Testing in case of discordant results
According to the criteria for a ‘true’ positive result,
only a positive MOMP PCR, a positive culture or a
positive DFA could conﬁrm another positive result
from the same site of sampling.
Statistical methods
Fisher’s exact test (two-tailed) was used for the
statistical calculations. P< 0.05 was considered
statistically signiﬁcant.
RESULTS
In total, 47 patients (32 males and 15 females) were
found to be C. trachomatis positive, corresponding
to a prevalence in this population of 11.5% (47/
410). The prevalence in male patients was 13.2%
(32/243), and that in female patients 9% (15/167).
Forty of 47 patients (85%) were diagnosed by
testing a urine sample, compared to 43 of 47
(91%) by testing swabs (cervical and/or urethral
swab). The difference in sensitivity between test-
ing urine samples and testing swabs did not reach
statistical signiﬁcance (Fisher’s exact test (two-
tailed), P¼ 0.5).
In four C. trachomatis-positive cases, the diag-
nosis was based on urine testing alone; two were
asymptomatic male patients tested as contacts, one
a male patient with dysuria and urethral dis-
charge, and one a female with dysuria who was
tested as a contact of a C. trachomatis-positive
partner. Therefore, the detection rate was in-
creased by 9% by testing a urine sample in con-
junction with testing swabs. In total, 14% (2/14) of
15 C. trachomatis-positive female patients had an
isolated urethral infection, as two patients were
positive only by sampling from the urethra (one
patient was positive by urine PCR, and one by
urine PCR as well as urethral swab PCR and
urethral swab culture). One patient did not have
a cervical swab taken at all.
The results of comparing the two different speci-
men types are presented in Table 1. The results are
presented in relation to the ‘true’ positive patient,
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with calculation of sensitivity, speciﬁcity and pre-
dictive values, after resolution of discordant
results. The difference between urine EIA and
urine PCR did not reach statistical signiﬁcance
(P¼ 0.4 and P¼ 0.7 (P¼ 0.5 and P¼ 1.0), respec-
tively, Fisher’s exact test (two-tailed)).
Upon testing urine samples by EIA, only 26 of 45
(58%) of 45 EIA-reactive urines (OD value cut-
off) could be conﬁrmed by DFA.
Of 24 urine samples that were EIA gray-zone
positive, three could be conﬁrmed byDFA and one
by MOMP PCR, and these four were considered
‘true’ positive results.
Of the tests on urine with PCR, 14 of 47 (30%)
were false negative according to the criteria for a
‘true’ positive result (nine samples were frommale
and ﬁve from female patients). Eight were later
found to be MOMP PCR positive. Six were EIA as
well as DFA positive (ﬁve were MOMP PCR posi-
tive), and one urine was EIA gray-zone positive,
DFA negative, and MOMP PCR positive.
On discrepancy testing, four of 17 PCR results
(24%) could not be reproduced by retesting (three
urine PCR results (two positive results and one
negative result) and one positive urethral swab
PCR).
Of two female patients with an initial positive
urine PCR, negative by retesting, negative by
MOMP PCR, and negative by urine EIA and
DFA, one had a positive urethral swab PCR, and
a positive cervical and urethral swab culture, and
the other had a positive urethral swab PCR and
culture. Both were considered urine PCR ‘true’
positive according to the criteria for a ‘true’ posi-
tive result. Apart from these two cases, there were
no false-positive PCR results.
Three gray-zone PCR-positive samples (two
urethral swabs and one urine sample) were nega-
tive by a repeated PCR and by a MOMP PCR, and
were considered true negative according to the
criteria for results.
In one case (a male patient), only urine EIA and
DFA were positive. The parallel samples were
negative. The patient was tested as a contact of
a C. trachomatis-positive partner without urethritis
symptoms according to the questionnaire.
For the conﬁrmation of a negative result, DFA
was performed on 23 urine samples representing
every 15th set of negative sample results, and
found to be negative for all 23 urine samples.
Data from the analysis of 320 completed ques-
tionnaires are presented in Table 2.
Information was available from 36 C. trachomatis
patients (information was not available for six
positive female patients and ﬁve C. trachomatis-
positive male patients). The median ages of C.
trachomatis-positive patients were 24.5 years (range
18–43 years) and 21 years (range 10–41 years) for
male and female patients, respectively.
In total, 23 of 36 patients (64%) complained of
symptoms compatible with a C. trachomatis infec-
tion. Eighteen of 27 (67%) male patients and ﬁve of
nine (56%) female patients were symptomatic,
corresponding to an asymptomatic carriage rate
of C. trachomatis of approximately 40%. Among
symptomatic C. trachomatis-positive patients, 80%
(4/5) of female patients and 88% (16/18) of male
patients were diagnosed by urine testing. In total,
of 117 patients (48 female and 69 male) complain-
ing of symptoms compatible with C. trachomatis
infection, 20% (23/117) were actually diagnosed as
having a C. trachomatis infection.
Table 1 Sensitivity, specificity, positive predictive value and negative predictive value of EIA, PCR and culture for each
specimen type calculated in relation to the ‘true’ C. trachomatis-positive patient among the female/male patients (n¼ 167/
243) and after resolving discordant results
Sensitivity
Female/male
(%/%)
Specificity
Female/male
(%/%)
PPV
Female/male
(%/%)
NPV
Female/male
(%/%)
EIA (urine) 40/62.5 94.1/95.3 40/66.7 94.1/94.4
(46.7/71.9) (94.1/95.3) (46.7/69.7) (94.7/95.7)
PCR (urine) 66.7a/71.9 100/100 100/100 96.8/95.9
PCR (swab) 93.3/87.5 100/100 100/100 99.3/98.1
Culture (swab) 93.3/87.5 100/100 100/100 99.3/98.1
aIncluded two PCR-positive urine results, negative by retesting and negative by MOMP PCR.
The figures in parentheses are the values calculated by including gray-zone-confirmed EIA results (one female urine and
three male urine were gray-zone EIA positive, confirmed by DFA or MOMP PCR).
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Thirty-one contacts with a C. trachomatis-posi-
tive individual were tested, and 11 (four female
and sevenmale) wereC. trachomatis positive (35%),
six of whom were symptomatic (two female and
four male).
Sixty patients (35 female and 25 male) were
tested as controls 4 weeks after treatment. In total,
3.3% (2/60) asymptomatic male patients were
positive. During the study period, only six of 36
C. trachomatis-positive patients had a later follow-
up test, of whom ﬁve were negative and one was
positive. One of these patients, a female, was
again positive 5 months later, after a negative
follow-up test 6 weeks after a positive one and
treatment.
DISCUSSION
We demonstrated a prevalence of C. trachomatis
infection of 11.5% among dermatovenerologic
patients, corresponding to the prevalence shown
by other studies from a similar study group [6,14–
18]. At least 40% of the patients or more had an
asymptomatic C. trachomatis infection.
By testing urine samples, we could diagnose
85% of the infections, compared to 91% diagnosed
by testing swabs.
Four more C. trachomatis-positive patients (three
male and one female, or 9%) were diagnosed by
testing urine in conjunction with swab(s). This
may indicate insufﬁciently rigorous urethral
swabbing, especially for male patients.
Up to 24% of female patients have isolated
urethral infection [19], and we demonstrated an
isolated urethra C. trachomatis infection in 14% of
the female population, indicating the importance
of supplying a cervical swab in addition to a
urethral swab or a urine sample.
In our study, culture and PCR performed
equally and very well on swabs, probably due
to a well-established culture laboratory and rapid,
cooled transport to the laboratory. The use of
indirect immunoﬂuorescence staining of inclu-
sions in cell culture instead of the iodine staining
we used in our study might have shown the
number of cases to be even higher [20].
Although culture is highly speciﬁc and, until
recently, was considered to be the ‘reference stan-
dard’ test, it is costly and laborious, and, for the
evaluation of the diagnostic efﬁcacy of the very
sensitive nucleic acid ampliﬁcation assays, an
expanded standard has been introduced [21].T
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The much higher sensitivity of PCR and ligase
chain reaction (LCR) on urine samples compared
to culture on swabs reported in other studies could
be caused by a suboptimal culture technique with
low sensitivity or different culture techniques
[14–16,22,23].
PCR on urine performed better than EIA on
urine in relation to the ‘true’ positive patient for
females, and equally well for males, by including a
30% negative gray zone for EIA (Table 1). How-
ever, there was a need for conﬁrmation of a posi-
tive EIA result by DFA, as only 58% of EIA-
positive results could be conﬁrmed by DFA. Our
study is similar to a study in which only 49% of
EIA-positive results (Syva Microtrak) could be
conﬁrmed by DFA [17].
The sensitivity of EIA was increased by 10% by
including a negative gray zone of 30%, but to
achieve this increase 24 gray-zone-positive urines
had to be tested by a DFA, which was quite
laborious. The advantages of EIA are ease of per-
formance, the possibility of running a large num-
ber of samples, and the fact that special laboratory
equipment is not necessary.
The only male patient diagnosed as ‘true’ C.
trachomatis positive by EIA conﬁrmed by DFA
might be a collection failure (see Results).The large
number of false-negative urine PCR results (30%)
could possibly be a result of inhibitors in the urine
samples, as repeated testing after freezing and
thawing turned one PCR-negative urine to PCR
positive, and ﬁve PCR-negative urines to MOMP
PCR positive.
Stary et al. found 33% false-negative PCR
(Amplicor) results when testing fresh urine sam-
ples [17].
Labile inhibitors in cervical mucus cannot be
removed by freezing and thawing, but can be
inactivated by a brief warming to 95 8C, or by
leaving at room temperature for 2 days [24–26].
A dilution of the sample, together with a brief
warming, was recommended in order to eliminate
inhibitors not removed by freezing and thawing
[26], or simply by diluting the sample prior to
testing [27–29].
A low number of C. trachomatis particles in the
sample may also give rise to a false-negative PCR
result [30], but only two of 14 patients with a PCR
false-negative urine result had less than 10 IFUs
in their corresponding urethral swabs (data not
shown). A false-positive PCR result could very
likely be true positive, as the conﬁrmatory MOMP
PCR is much less sensitive than plasmid PCR
[31].
The PCR results did not reproduce very well
corresponding with results from other studies
[24,32].
The fact that 35% of contacts tested positive
emphasizes the importance of contact tracing.
Two asymptomatic male controls (3.3%) tested
C. trachomatis positive, 4 weeks after a single 1.0-g
dose of azithromycin. Only six of the C. trachoma-
tis-positive patients diagnosed during the study
returned for a later follow-up test after treatment.
A single 1.0-g dose of azithromycin is as effec-
tive as a standard 7-day cure of doxycycline, and
gives a higher compliance rate [33–35]. Our cases
could be treatment failures or reinfections. We
must therefore recommend a conﬁrmation of cure
4 weeks after treatment in a high-risk population
in order tominimize the spread of C. trachomatis.A
home-collected, mailed urine sample tested by
PCR/LCR could be suggested for this purpose
[9]. A fear of false-positive results after treatment,
especially by antigen tests and ampliﬁcation tests,
has been expressed, but positive results are turn-
ing negative at least 2 weeks after a treatment was
initiated [36,37]. A conﬁrmation of cure might not
be cost-effective, and instead a follow-up visit was
recommended about 2 weeks after treatment was
initiated, with a new test only in cases of possible
reinfection, lack of compliance or treatment failure
[38–40].
In conclusion, we found that a urine sample
worked well in this population of symptomatic
and asymptomatic STD patients for the diagnosis
of urogenital C. trachomatis infection. However,
testing a urine sample is not straightforward.
Urine EIA gave a large number of false-positive
results, whereas urine PCR was characterized by
toomany false-negative results, most likely caused
by inhibitors. The optimal way to diagnose a C.
trachomatis infection is to add a urine sample to
conventional swab(s) for assessment, instead of
replacing a swab by a urine sample. When a urine
sample was tested in addition to a swab, the
detection rate was increased by 9%. As two
(3.3%) asymptomatic male follow-up patients
were found to be C. trachomatis positive 4 weeks
after therapy was initiated, we think that a con-
ﬁrmation of cure is advisable to minimize the
spread of C. trachomatis infections, together with
partner notiﬁcation, as 35% of contacts tested
positive.
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